Filipa C. Lynce
Oncology
450 Brookline Avenue
Susan F. Smith Center For Women's Cancers
Boston, MA 02115
Susan F. Smith Center For Women's Cancers
Boston, MA 02115
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 109 publications
Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary.
Journal: Future oncology (London, England)
Published: June 22, 2026
Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer.
Journal: JAMA network open
Published: April 09, 2026
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 10, 2026
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 02, 2026
Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies.
Journal: JNCI cancer spectrum
Published: January 29, 2026
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.
Journal: The New England journal of medicine
Published: January 28, 2026
Real-world clinical outcomes of patients with early-stage TNBC and BRCAm who were treated with adjuvant capecitabine in the United States.
Journal: Breast cancer research and treatment
Published: January 09, 2026
Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practice.
Journal: Breast (Edinburgh, Scotland)
Published: December 22, 2025
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer.
Journal: ESMO open
Published: November 04, 2025
Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer.
Journal: Cell reports. Medicine
Published: October 30, 2025
Last Updated: 09/26/2026